Cargando…
Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes
BACKGROUND: Eculizumab modifies the course of disease in patients with atypical haemolytic uraemic syndrome (aHUS), but data evaluating whether eculizumab discontinuation is safe are limited. METHODS: Patients enrolled in the Global aHUS Registry who received ≥1 month of eculizumab before discontinu...
Autores principales: | Ariceta, Gema, Fakhouri, Fadi, Sartz, Lisa, Miller, Benjamin, Nikolaou, Vasilis, Cohen, David, Siedlecki, Andrew M, Ardissino, Gianluigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894930/ https://www.ncbi.nlm.nih.gov/pubmed/35261761 http://dx.doi.org/10.1093/ckj/sfab005 |
Ejemplares similares
-
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
por: Macia, Manuel, et al.
Publicado: (2017) -
Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017) -
Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012) -
Outcome of atypical haemolytic uraemic syndrome relapse after
eculizumab withdrawal
por: Duineveld, Caroline, et al.
Publicado: (2020) -
Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study
por: Menne, Jan, et al.
Publicado: (2018)